Design, synthesis and in vivo antitumor activity of novel 3, 4 di-substituted quinazoline derivatives
DOI:
https://doi.org/10.7439/ijpc.v7i1.3928Abstract
Objective: The present investigation is designed to synthesize some new isomeric series of quinazoline-4-one/4-thione derivatives, depending upon on the pharmacophoric model of in-vivo anticancer activity by modifying the structures retaining the fundamental structural features for the activity and screened for their antitumor properties. Methods: A new series of 7-chloro-3-[substituted (amino/phenyl amino)]-2-phenyl quinazolin-4 (3H)-one/thione derivatives and 1-(7-chloro-4-oxo/-2-phenylquinazoline-3 (4H-yl)) substituted urea derivatives were synthesized. The reaction scheme proceeds through 7-chloro-2-phenyl-4H-benzo [d] [1, 3] oxazin-4-one which is the intermediate one. The structures of the newly synthesized compounds were characterised from infrared (IR), H1 nuclear magnetic resonance (NMR) and mass spectra (m/z) and elemental analysis. The in-vivo antitumor activity was evaluated by body weight analysis, mean survival time and percentage increase in life span methods in Swiss albino mice bearing Ehrilich ascites carcinoma (EAC). Result: The physico-chemical and spectroscopic data established the synthesis of quinazoline derivatives with a common pharmacophore. The synthesized compounds were evaluated for their antitumor properties. Among the newly quinazoline derivatives screened, six compounds (IIh, IIi, IIj, IIIh, IIIi, IIIj)) have shown significant antitumor activity. Conclusion: The quinazoline derivatives obtained from the present study indicates that the amino group at 3rd position and urea/thiourea group in phenyl hydrazine ring at 3rd position of quinzoline skeleton are essential for antitumor activity. Compounds IIh, IIi, IIj, IIIh, IIIi and IIIj were found to be biologically active which may be useful as potential resource for the discovery of anti-tumor compound having common quinazoline pharmacophore with lesser toxic effects.Downloads
References
Adel S, Azab E, Mohamed A, Omar A, Alaa AM, Naglaa I, et al. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study. Eur J Med Chem 2010; 45:4188-98.
Sarah TAR, Ihsan AA, Mahmoud NN, Laila AA, Alaa AMA, Sami GA, et al. Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4 (3H)-quinazolinone analogs. Bioorg Med Chem 2006; 14(24): 8608-21.
Al-Obaid AM, Abdel-Hamide SG, El-Kashef HA, Alaa AM, El-Azab AS, Al-Khamees HA, et al. Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4 (3H)-quinazolinone analogs. Eur J Med Chem 2009; 44: 2379-91.
Al-Omary FAM, Abou-zeid LA, Al-omar MN, Al-obaid AM, El-Subbagh HI. Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2, 6-substituted-quinazolin-4-ones. Bioorg Med Chem 2010; 18: 2849-63.
Donner, EJ, Snead OC III. New generation anticonvulsants for the treatment of epilepsy in children. NeuroRx 2006; 3: 170-80.
Honkanen E, Pippori A, Kairisalo P, Nore P, Karppanen H, Paakkari I. Synthesis and antihypertensive activity of some new quinazoline derivatives. J Med Chem 1983: 26: 1433-38.
Beena KP, Akelesh T. Synthesis and antibacterial activity of quinazolinone derivatives. Int J Pharm Pharm Sci 2010; 2: 166-168.
Al-Omar MA, El-Azab AS, El-Obeid HA, Abdel Hamide SG. Synthesis of some new 4-(3H)-quinazoline analogs as potential antioxidant Agents. J Saudi Chem Soc 2006; 10: 111-28.
Kumar A, Sharma S, Archana A, Bajaj K, Sharma S, Panwar H, et al. Some new 2, 3, 6-trisubstituted quinazolinones as potent anti-inflammatory, analgesic and COX-II inhibitors. Biorg Med Chem 2003: 11: 5293-99.
Kashaw SK, Kashaw V, Mishra P, Jain NK, Stables JP. Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea. Eur J Med Chem 2009; 44: 4335-43.
Dash B, Dash S, Laloo D. Design and synthesis of 4-substituted quinazoline derivatives for their anticonvulsant and CNS depressant activities, Int J Pharm Pharm Sci 2017; 9: 165-172.
Hanan G. Synthesis, Cytotoxic Activity and 2D-QSAR study of some imidazoquinazoline derivatives. Molecules 2014; 19: 3777-92.
Cai J, Sun M, Wu X, Chen J, Wang P, Zong X, et al. Design and synthesis of novel 4-benzothiazole amino quinazolines dasatinib derivatives as potential anti-tumor agents. Eur J Med Chem 2013; 63: 7002-12.
Wang Y, Jin J, Zhu L, Zhang Y, Chen X, Gao X, et al. Synthesis and anti tumor activity of novel 2-(1-substituted
Yinjiu H, Fang L, Li Z, Huazhang W, Hui L, Yinjiu H, et al. Antitumor activity of 4-(4-flurophenyl) amino-5,6,7 trimethoxy quinazoline against tumor cells in vitro. Cell Biol Int 2012; 36: 377-82.
Ilangovan P, Ganguly S, Pandit V. Design and synthesis of novel quinazolinone derivatives as broad spectrum anticonvulsant and antimicrobial Agent. J Pharm Res 2010; 3:703-6.
Hemlata K, Girija K. Synthesis of some novel 2, 3 disubstituted quinazolinone derivatives as analgesic and anti-inflammatory agents. Int J Pharm Pharm Sci 2011; 3:103-6.
Litchfield JR, Wilcoxon FA. Simplified method of evaluating dose effect experiments. J Pharmacol Exp Ther 1999; 96: 99-113.
Eckhardt AE, Malone BN, Goldstein IJ. Inhibition of ehrlich ascites tumour cell growth by Griffonia Simplifolia lectin in vivo. Cancer Res 1982; 42: 2977-79.
Sathisa MP, Revankar VK, Pai KSR. Synthesis, structure, electro chemistry and spectral characterization of bis-isatin thiocarbohydrazone metal complexes and their antitumor activity against ehrlich ascites carcinoma in swiss albino mice. Met based drugs 2007; 2008: 1-11.
Mukherjee A, Dutta S, Sanyal U. Evaluation of Dimethoxydop-NU as a novel antitumor agent. J Exp Clin Cancer Res 2007; 26: 489-97.
Ma Y, Mizuno T, Ito H. Antitumor activity of some polysaccharides isolated from a chinese mushroom,
Chihara G, Hamuro J, Maefa YY, Aria Y, Fukuoka F. Fractionation and purification of the polysaccharides with marked antitumor activity, especially from lentinan, from Lentinus edodes (berk).Sing. (an edible mushroom). Cancer Res 1970; 30: 2776-81.
Kameshwaran S, Suresh V, Arunachalam G, Kanthlal SK, Mohanraj M, In vitro & In vivo anticancer activity of methanolic extact of Tecoma Stans flower. Int Res J Pharm 2012; 3: 246-51.
Hogland HC. Haematological complications of cancer chemotherapy. J Oncol 2007; 9: 95-102.
Gupta M, Mazumder UK, Rath N, Mukhopadhyay DK. Antitumor activity of methanol extract of Cassia fistula L. seed against ehrlich ascites carcinoma. J Ethnopharma 2000; 72: 151-56.
Sridharan G, Brindha P, Raja R, Amutha Priya R. In-vitro and in-vivo cytotoxic effect of Salvia Leucantha cav. against EAC cell lines. Int J Pharm Pharm Sci 2012; 4: 143-46.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
- The author must submit Copyright form After acceptance of the article.
How to Cite
